RxDoctor Payments DataLook up a doctor →

Sabrina Roberts, MD

Pulmonary Disease · Ashland, KYNPI 1841475100

Payments from drug & device makers

$15,200in general payments, 2019–2025

Across 823 payments — averaging $18.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$4K
  • AstraZeneca$2K
  • Boehringer Ingelheim$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$851
  • Electromed, Inc.$667
  • Mylan Specialty L.p.$633
  • plus $6K from 33 others

What the payments were for

  • Food & beverage$14,87898%
  • Education$3212%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,200 in reported general payments places this provider in the 80th percentile of 226 pulmonary disease providers in Kentucky.

See all pulmonary disease providers in Kentucky

Medicare billing

Part B allowed, 2024
$93,244
Medicare patients
604
Services billed
1,123

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter259$275,934
Prolastin CAlpha-1-Proteinase Inhibitor11$131,072
Spiriva RespimatTiotropium Bromide70$64,404
Stiolto RespimatTiotropium Br/Olodaterol Hcl62$48,085
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr60$34,953
Breztri AerosphereBudesonide/Glycopyr/Formoterol39$34,190
Breo ElliptaFluticasone/Vilanterol25$17,819
Albuterol Sulfate HfaAlbuterol Sulfate310$13,742
Spiriva HandihalerTiotropium Bromide15$10,216
Incruse ElliptaUmeclidinium Bromide15$8,710
SymbicortBudesonide/Formoterol Fumarate17$7,020
Ventolin HfaAlbuterol Sulfate81$5,891
Modafinil45$5,529
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate25$5,039
Fluticasone-SalmeterolFluticasone Propion/Salmeterol24$4,714

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$3,619$337,416359 claims
Grifols USA, LLCProlastin C$515$131,07211 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$1,272$112,489132 claims
AstraZenecaBreztri Aerosphere, Symbicort$2,080$41,21056 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 226 pulmonary disease providers in Kentucky.

Other pulmonary disease in Ashland

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →